Search research articles
Contact Us
Filters
Showing results (51-60 of 84) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
March 12, 2013
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Somnath Mukherjee, Christopher N Hurt, John Bridgewater, et al.
Clinical and Translational Radiation Oncology
|
February 20, 2020
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
Julia Murray, Sarah Gulliford, Clare Griffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 27, 2019
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
Julia Murray, Clare Griffin, Sarah Gulliford, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 12, 2018
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
David Dearnaley, Clare L Griffin, Rebecca Lewis, et al.
Health Technology Assessment (Winchester, England)
|
July 20, 2016
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
Nicholas James, Sarah Pirrie, Ann Pope, et al.
NIHR Open Research
|
October 25, 2023
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial
Paul Gravestock, Emma Clark, Miranda Morton, et al.
JNCI Cancer Spectrum
|
October 3, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response
Chris Parker, Nina Tunariu, Holly Tovey, et al.
The Lancet. Oncology
|
December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David Dearnaley, Isabel Syndikus, Georges Sumo, et al.
Clinical and Translational Radiation Oncology
|
October 14, 2022
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation
Julia Murray, Clare Cruickshank, Thomas Bird, et al.
Clinical and Translational Radiation Oncology
|
February 24, 2026
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT
Angela Pathmanathan, Suneil Jain, John Staffurth, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 84) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
March 12, 2013
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Somnath Mukherjee, Christopher N Hurt, John Bridgewater, et al.
Clinical and Translational Radiation Oncology
|
February 20, 2020
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
Julia Murray, Sarah Gulliford, Clare Griffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 27, 2019
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
Julia Murray, Clare Griffin, Sarah Gulliford, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 12, 2018
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
David Dearnaley, Clare L Griffin, Rebecca Lewis, et al.
Health Technology Assessment (Winchester, England)
|
July 20, 2016
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
Nicholas James, Sarah Pirrie, Ann Pope, et al.
NIHR Open Research
|
October 25, 2023
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial
Paul Gravestock, Emma Clark, Miranda Morton, et al.
JNCI Cancer Spectrum
|
October 3, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response
Chris Parker, Nina Tunariu, Holly Tovey, et al.
The Lancet. Oncology
|
December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David Dearnaley, Isabel Syndikus, Georges Sumo, et al.
Clinical and Translational Radiation Oncology
|
October 14, 2022
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation
Julia Murray, Clare Cruickshank, Thomas Bird, et al.
Clinical and Translational Radiation Oncology
|
February 24, 2026
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT
Angela Pathmanathan, Suneil Jain, John Staffurth, et al.
Page
of 9